Status:

TERMINATED

Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease

Lead Sponsor:

Atlas Biomed

Conditions:

Parkinson Disease

Genetic Predisposition

Eligibility:

All Genders

45+ years

Brief Summary

A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.

Detailed Description

Two groups of subjects - one including healthy individuals and the other - treatment-naive patients with incident Parkinson's disease - will fill in the food frequency questionnaire, SF-36 questionnai...

Eligibility Criteria

Inclusion

  • Men and women aged 45 years and over who have been diagnosed with Parkinson's disease
  • Subject signed informed consent

Exclusion

  • Gastroenterological diseases such as ulcerative colitis, Crohn's disease, celiac disease, gallbladder diseases (calculous cholecystitis, cholangitis, etc.) that are not related to functional disorders, a liver diseases or pancreas in medical history
  • Exacerbations of chronic gastroenterological diseases
  • Mental illness
  • Oncology diseases
  • Mental disorders
  • Rheumatoid arthritis or other autoimmune diseases
  • Acute infectious diseases or exacerbation of any diseases
  • Recent (\<3 months) administration of proton pump inhibitors, antimicrobial therapy or surgical intervention
  • Recent (\<3 weeks) use of probiotics, antacids, nonsteroidal anti-inflammatory drugs, laxatives
  • Recent (\<14 days) administration of laxatives (excluding prucaloprid)
  • Recent (\< 3 months) surgical intervention
  • Pregnancy, planning to be pregnant or breast feeding at any point during the study or study enrollment
  • Current alcohol/drug abuse (more than 3 points for women and 4 for men according to AUDIT-C questionnaire and/or more than 7 points on the AUDIT questionnaire) or addiction therapy within 12 months prior to screening
  • Planned relocation from the home region during the study
  • Stroke in medical history
  • Any surgical intervention in the central nervous system
  • Morbid obesity, BMI\> 35 kg / m2
  • A medical history of carriage or disease associated with a history of human immunodeficiency viruses, hepatitis B, C or Treponema pallidum
  • The patient's inability to understand the essence of the study and agree to participate in it. MoCA scores \<22
  • 4-5 stage of the disease according to the Hen and Yara scale
  • Severe somatic pathologies or any factors that, in the opinion of the doctor, may prevent the patient from being included in the study
  • A medical history of serious head injuries
  • Rheumatoid arthritis
  • Tuberculosis

Key Trial Info

Start Date :

September 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 25 2022

Estimated Enrollment :

138 Patients enrolled

Trial Details

Trial ID

NCT04119596

Start Date

September 1 2020

End Date

February 25 2022

Last Update

July 21 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Siberian State Medical University

Tomsk, Russia